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Influenza virus transcription occurs in the nuclei of infected cells, where the viral genomic RNAs are com-
plexed with a nucleoprotein (NP) to form ribonucleoprotein (RNP) structures. Prior to assembly into progeny
virions, these RNPs exit the nucleus and accumulate in the cytoplasm. The mechanisms responsible for RNP
export are only partially understood but have been proposed to involve the viral M1 and NS2 polypeptides. We
found that the drug leptomycin B (LMB), which specifically inactivates the cellular CRM1 polypeptide, caused
nuclear retention of NP in virus-infected cells, indicating a role for the CRM1 nuclear export pathway in RNP
egress. However, no alteration was seen in the cellular distribution of M1 or NS2, even in the case of a mutant
virus which synthesizes greatly reduced amounts of NS2. Furthermore, NP was distributed throughout the
nuclei of infected cells at early times postinfection but, when retained in the nucleus at late times by LMB treat-
ment, was redistributed to the periphery of the nucleoplasm. No such change was seen in the nuclear distri-
bution of M1 or NS2 after drug treatment. Similar to the behavior of NP, M1 and NS2 in infected cells, LMB
treatment of cells expressing each polypeptide in isolation caused nuclear retention of NP but not M1 or NS2.
Conversely, overexpression of CRM1 caused increased cytoplasmic accumulation of NP but had little effect on
M1 or NS2 distribution. Consistent with this, NP bound CRM1 in vitro. Overall, these data raise the possibility
that RNP export is mediated by a direct interaction between NP and the cellular CRM1 export pathway.
The influenza virus genome consists of eight segments of
single-stranded RNA that encode a total of 10 identified poly-
peptides. The genomic RNA segments are of negative sense
and are always found in association with viral polypeptides: the
three subunits of an RNA-dependent RNA polymerase (PB1,
PB2, and PA) and, in stoichiometric quantities, a single-strand
RNA-binding nucleoprotein (NP) (28). In virions, these ribo-
nucleoprotein (RNP) structures are packaged within a shell of
the viral M1 polypeptide underlying the lipid bilayer, along with
the hemagglutinin (HA) and neuraminidase integral mem-
brane glycoproteins. Minor virion components include M2, a
small transmembrane ion channel, and the NS2 polypeptide
(28). Influenza virus particles enter the cell by receptor-medi-
ated endocytosis. Following acidification of the endosome, the
M1 polypeptide dissociates from the RNP segments and virion
RNPs (vRNPs) are released into the cytoplasm (30, 31). Un-
usually for a virus with no DNA coding stage, influenza virus
transcription occurs in the nucleus (20, 22). Accordingly, after
release of the RNPs into the cytoplasm, they migrate into the
nucleus, in an active process that is thought to be mediated by
the cellular importin a/b pathway (39). Once in the nucleus,
vRNPs act as the template for synthesis of mRNAs, which
are exported into the cytoplasm for translation. The vRNPs
also act as the template for synthesis of full-length cRNA
copies of the genome, which are encapsidated by NP and act as
replicative intermediates for the synthesis of progeny genomic
RNA (28). Transcription and replication of the viral genome
require the three components of the RNA-dependent RNA
polymerase in addition to NP (21). These proteins, together
with newly synthesized virion RNA, are assembled into RNPs
in the nucleus. However, since progeny virion formation occurs
at the plasma membrane, this necessitates nuclear export of
the new RNPs. This occurs by a process that is still only par-
tially understood. Current evidence implicates three virus
polypeptides: M1, NS2, and NP itself. RNP export fails in the
absence of M1, either in the case of defective viruses (29) or in
the absence of late gene expression (4, 29, 51), while microin-
jection of antibodies to M1 effectively blocks the process of
RNP export (29). However, the temperature-sensitive (ts) virus
ts51 accumulates M1 in the nucleus at the nonpermissive tem-
perature but is still able to export RNPs, suggesting that it is
not necessary for M1 to be transported across the nuclear
envelope in stoichiometric quantities (41, 52). It has recently
been proposed that NS2 plays a major role in the transport of
vRNPs out of the nucleus (38). Although NS2 does not interact
directly with RNPs, it binds to M1 associated with vRNPs (54).
Furthermore, NS2 contains a functional nuclear export signal
(NES) and interacts with components of the nuclear pore
complex (NPC) in a yeast two-hybrid system (38). Accordingly,
it has been suggested that NS2 acts as an adapter molecule that
links M1-RNP complexes with the NPC, thus mediating their
export across the nuclear envelope (38). However, an influenza
virus mutant that synthesizes greatly reduced amounts of NS2
replicates normally (44, 53). Similarly, in infected cells with a
block to late gene expression, RNP export could be restored by
the addition of exogenous M1 in the absence of detectable NS2
(4). Therefore, the virus may have evolved more than one
mechanism to transport RNPs across the nuclear envelope.
Supporting this possibility, evidence suggests that NP contains
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an intrinsic NES: although it contains two or more nuclear
localization signals (5, 35, 49, 50), exogenously expressed NP
shuttles between the cytoplasm and nucleus (51) and does not
necessarily accumulate in the nucleus. Factors promoting cy-
toplasmic accumulation of NP include cellular hyperphospho-
rylation, increased time or levels of NP expression, and the
ability of the protein to bind F-actin (9, 35).
Thus, although a plausible and attractive hypothesis has
been suggested to explain nuclear export of RNPs late in in-
fection (38), several experimental observations suggest that the
process is more complex. To date, there has been no investi-
gation of the possible role of the cellular nuclear export path-
way mediated by CRM1 in the export of influenza virus RNPs.
CRM1, or exportin 1, is a member of the importin b family,
members of which are important in the transport of a variety of
proteins in both directions across the nuclear envelope (32). In
addition to associating with components of the NPC (16),
CRM1 acts as a soluble adapter molecule that binds to leucine-
rich NESs in the nucleoplasm and, together with RanGTP,
forms a trimeric complex that mediates export of the substrate
(15, 46). Many cellular and viral proteins that contain nuclear
export signals have been shown to interact with the CRM1
pathway, which therefore appears to act as a general export
receptor for proteins and RNA complexes (8, 11).
As a specific inhibitor of CRM1 function, the cytotoxin lep-
tomycin B (LMB) provides a useful reagent for studying nu-
clear export in cells. LMB inhibits CRM1-mediated nuclear
export of a range of proteins and RNAs (2, 11, 15, 45) by co-
valently modifying a specific cysteine residue in CRM1, which
is thought to interfere with the formation of a stable complex
with the export substrate (24, 25). Here, we show that LMB
treatment retained influenza virus RNPs in the nuclei of in-
fected cells, implying a role for the CRM1 pathway in their
export. However, the drug did not alter the cellular distribution
of either M1 or NS2, even in the context of a virus mutant that
expresses around 5% of the normal amount of NS2. Moreover,
LMB treatment caused the nuclear retention of transfected NP
while, conversely, overexpression of CRM1 caused increased
cytoplasmic accumulation. Neither LMB treatment nor CRM1
overexpression significantly affected the localization of exog-
enously expressed M1 or NS2. Thus, NP interacts with the
CRM1 pathway in the absence of other influenza virus poly-
peptides and, consistent with this, we show that NP and CRM1
interact in vitro. This raises the possibility that nuclear export
of influenza virus RNPs involves a direct interaction between
NP and the CRM1 export pathway.
MATERIALS AND METHODS
Viruses, plasmids, and antibodies. Influenza virus strains A/PR/8/34 (PR8)
and A/FPV/Rostock/34 (FPV) and the temperature-sensitive FPV mutant mN3
(53) were propagated in 10-day-old embryonated eggs for 2 days at either 37°C
(PR8) or 34 (FPVs). The virus mN3 contains a temperature-sensitive lesion in
segment 8 which blocks replication at elevated temperatures and an incompletely
mapped lesion, probably also in segment 8, which leads to decreased segment 8
splicing at the permissive temperature (44, 53). Recombinant vaccinia virus
expressing T7 polymerase, vTF7, has been described previously (17). Plasmids
expressing wild-type (WT) or mutant NP genes under control of the T7 promoter
(pKT5 series) or as glutathione S-transferase (GST) and maltose-binding protein
(MBP) fusions have also been described previously (9, 13). pCDNA-CRM1 (2)
was kindly provided by S. Swaminathan and G. Grosveld, pT7-hSRP1 was from
H. Kent and M. Stewart (MRC Laboratory of Molecular Biology, Cambridge,
United Kingdom), pGEM-NS2 (encoding NS2 from influenza virus strain A/Vic-
toria/3/75) was from A. Portela (34), and pT7-703, containing the cDNA of
segment 7 from A/PR/8/34 subcloned from pAPR701 (55) under control of a T7
RNA polymerase promoter, was from S. Inglis (Cantab Pharmaceuticals Ltd.,
Cambridge, United Kingdom). LMB was the generous gift of M. Yoshida and
was dissolved in ethanol and stored under argon at 220°C (24, 36). LMB was
added to culture medium to a final concentration of 11 nM; this value was chosen
after initial titration experiments indicated that concentrations of $5 nM were
required for nuclear retention of NP and transportin, a marker cellular polypep-
tide (data not shown). Polyclonal rabbit serum raised against PR8 NS2 has been
described previously (10); rabbit anti-RNP and anti-PR8 sera were generously
provided by S. Inglis. For double staining of NP and NS2, anti-RNP and anti-NS2
immunoglobulin G sera were purified on protein A-Sepharose and then conju-
gated to either fluorescein isothiocyanate (Sigma) or Cy3 (Amersham) fluoro-
phore using the manufacturer’s recommended protocol. A monoclonal antibody
to influenza virus M1 was kindly provided by B. A. Askonas (19), and anti-
nucleoporin p62 (Nup62) monoclonal antibody was obtained from Transduction
Laboratories.
Cell fractionation. Cells were fractionated essentially as described by Briedis
et al. (3). Briefly, BHK cells in 60-mm-diameter dishes were harvested at various
times postinfection by scraping into 1 ml of ice-cold phosphate-buffered saline
(PBS) and pelleted by centrifugation at 12,000 3 g for 1 min. Cell pellets were
resuspended in 100 ml of ice-cold TMN buffer (10-mM Tris-HCl [pH 7.2], 1.5
mM MgCl2, 140 mM NaCl) containing 0.5% NP-40 and 0.5% Triton X-100,
vortexed, and then incubated on ice for 30 min. Following centrifugation at
600 3 g for 5 min at 4°C, the supernatants were transferred to a fresh tube and
pellets (nuclei) were resuspended in 200 ml of sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) sample buffer. Equivalent proportions
of the two fractions were analyzed by SDS-PAGE and Western blotting. Frac-
tionation efficiency was confirmed by Western blotting for influenza virus HA
and b-actin as well as the difference in NP distribution between early and late
times postinfection (data not shown).
Labeling of cells with [35S]methionine. Chicken embryo fibroblast (CEF) cells
were seeded on 24-well plates and grown on confluency in M199 medium con-
taining 10% fetal calf serum. Cells were infected with influenza virus (FPV or
mN3) in allantoic fluid diluted in medium at a multiplicity of infection (MOI) of
10 PFU/cell for 60 min at room temperature (RT) and then incubated at 34°C in
M199 medium containing 2% fetal calf serum with or without 11 nM LMB. Cells
were transferred to methionine-free M199 medium for 30 min prior to labeling
and then labeled for 30 min in 160 ml of medium containing 100 mCi of [35S]me-
thionine (Amersham) per ml with or without LMB. After labeling, cells were
harvested in 200 ml of SDS-PAGE sample buffer.
Transfections and immunofluorescence. BHK cells seeded on glass coverslips
were infected with vTF7 at an MOI of 5 PFU/cell and transfected 2 h later with
0.01 to 1.0 mg of plasmid DNA using Lipofectin (GIBCO-BRL) according to the
manufacturer’s directions. LMB was added to desired wells at a final concentra-
tion of 11 nM at 3 h posttransfection. Cells were harvested 2 h later and fixed for
20 min in 4% formaldehyde in PBS. Cells infected with influenza virus at an MOI
of 10 PFU/cell were fixed in the same way. After permeabilization with 0.2%
Triton X-100 in PBS for 5 min at room temperature, cells were incubated for 1 h
with rabbit polyclonal anti-RNP serum at 1/250 to stain for NP, anti-PR8 serum
at 1/500 to stain for M1, or anti-NS2 serum at 1/200. Cells were then incubated
with fluorescein isothiocyanate-conjugated swine anti-rabbit antibodies (Dako)
at 1/200 for 30 min at RT. For double staining of PR8-infected cells, directly
labeled anti-RNP and anti-NS2 sera were used at a 1/100 dilution for 1 h at RT;
an M1 monoclonal antibody was used at 1/150 with anti-mouse Alexa 594 (Mo-
lecular Probes) at 1/1,000. Coverslips were mounted in Citifluor and examined
using a Leitz Orthoplan microscope or a Leica TCS SP confocal microscope. To
generate images of whole cells, serial optical planes of focus (at ;0.5-mm inter-
vals) were taken on the z axis, across the depth of the cell, and merged into one
image (using extended focus or projection algorithms) by the software package
TCS-NT (Leica). Unless otherwise stated, laser power and photomultiplier tube
settings were kept identical between matching samples stained with the same
antibody. For numerical analysis of influenza virus polypeptide distribution in
transfected cells, typically around 100 fluorescent cells per coverslip were exam-
ined and scored according to whether the observed fluorescence was predomi-
nantly cytoplasmic (C), predominantly nuclear (N), or throughout the cell (N/C).
For statistical analysis, numbers of transfected cells falling into the various
categories after addition of CRM1 and/or LMB were compared against the
distribution obtained in the absence of other agents using the x2 test. In certain
cases, sums of the N/C and C categories were used to reduce the influence of the
relatively low-number C category.
In vitro translation and protein binding assays. Radiolabeled CRM1, hSRP1,
NS2, and NP were synthesized using a coupled in vitro transcription-translation
VOL. 75, 2001 NUCLEAR EXPORT OF INFLUENZA VIRUS RNPs 409
system (7) as described previously (12). MBP and GST fusion proteins were
affinity purified from lysates of Escherichia coli as described previously (9) and
left bound to Sepharose beads. Protein binding assays were carried out essen-
tially as described earlier (12). A 50-ml volume of a 50% slurry of glutathione-
Sepharose (Pharmacia) or amylose resin (New England Biolabs) containing
approximately 1 mg of fusion protein was incubated with 1 ml of in vitro-trans-
lated protein in 150 ml of IP buffer (100 mM KCl, 50 mM Tris-Cl [pH 7.6], 5 mM
MgCl2, 1 mM dithiothreitol, 0.1% NP-40) for 1 h at RT. Bound proteins were
collected by centrifugation, washed three times with 750 ml of IP buffer, resus-
pended in 30 ml of SDS-PAGE sample buffer, and analyzed by SDS-PAGE and
autoradiography.
RESULTS
LMB inhibits nuclear export of NP in influenza virus-in-
fected cells. Recently, it has been proposed that nuclear export
of influenza virus RNPs is mediated by the viral NS2 protein
via its NES and ability to interact with cellular nucleoporins
(38). In this model, NS2 binds to M1-RNP complexes through
interactions with M1 and facilitates nuclear export by direct
contact with components of the NPC. However, many proteins
that contain NESs interact with the cellular protein CRM1,
which appears to act as a general export receptor (8, 11).
To test the involvement of CRM1 in the nuclear export of
influenza virus RNPs, BHK cells were infected with virus,
treated with 11 nM LMB 1 h postinfection (hpi), and analyzed
by indirect immunofluorescence after a further 11 h. In un-
treated cells, NP localized predominantly to the cytoplasm,
with many cells having apparently empty nuclei (Fig. 1a). This
is the expected pattern of NP staining late in infection (29),
consistent with most of the RNPs having exited the nucleus for
assembly into progeny virions. In contrast, cells treated with
LMB showed a dramatic change in NP distribution, with the
majority of cells showing nuclear accumulation of the polypep-
tide (Fig. 1b) and very little cytoplasmic staining, indicating a
block to the export of RNPs.
To confirm the change in NP distribution induced by LMB,
virus-infected cells incubated in the absence or presence of the
inhibitor were separated into nuclear and cytoplasmic fractions
at different times postinfection and analyzed by Western blot-
ting for NP content. Since immunofluorescence time course
experiments indicated that the switch in NP localization from
predominantly nuclear to predominantly cytoplasmic occurred
at about 5 h in BHK cells and was essentially complete by 9 h
postinfection (data not shown), measurements were made at
time points from 6 h onward. In cells without drug treatment,
the proportion of NP in the cytosolic fraction was greater than
that in the nuclear fraction at all of the time points tested (Fig.
2). This is consistent with the immunofluorescence data, which
showed that NP was predominantly cytoplasmic at late times
postinfection. The overall amount of NP increased with time
postinfection, indicating continued synthesis of the polypep-
tide. In contrast, in the presence of LMB, the majority of the
NP was found in the nuclear fractions, particularly at earlier
times postinfection (Fig. 2).
Previous studies have shown that use of the protein kinase
inhibitor H7 also causes retention of influenza virus RNPs in
the nucleus, in part by blocking the synthesis of late viral
proteins, including M1 and NS2 (4, 26, 29, 48). To directly
examine the effect of LMB on viral protein synthesis, BHK
cells were infected with PR8 in the presence or absence of
LMB and harvested at 13 hpi and cell extracts were analyzed
by SDS-PAGE and Western blotting. No difference was ob-
served in the level of synthesis of HA0, NP, or M1 between
FIG. 1. Effect of LMB treatment on the intracellular localization of
influenza virus polypeptides. BHK cells were infected with 10 PFU of
influenza A/PR/8/34 virus per cell; incubated from 1 hpi in the absence
(a, c, and e) or presence (b, d, and f) of 11 nM LMB, and examined at
12 hpi by confocal microscopy after staining for NP (a and b), M1 (c
and d), or NS2 (e and f). Images were generated using an extended-
focus algorithm.
FIG. 2. Effect of LMB on the distribution of viral RNPs between
the nuclear and cytoplasmic cell fractions. BHK cells were infected
with PR8 at an MOI of 10 PFU/cell, incubated from 1 hpi in the
presence or absence of 11 nM LMB, and harvested at 6, 8, and 9 h
postinfection. Cells were separated into nuclear (N) and cytosolic (C)
fractions, and equivalent amounts were subjected to SDS-PAGE and
Western blotting with anti-RNP serum. Samples of purified virus (lane
v) were also analyzed in parallel to provide a marker for NP. M, mock
infected.
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treated and untreated infected cells (Fig. 3a). Additionally, no
decrease in synthesis of the polymerase proteins or NS1 was
observed when protein synthesis was examined by metabolic
labeling (data not shown, but see later for FPV). Thus, we
found no evidence that LMB acts by altering viral protein
synthesis.
Since LMB is a specific inhibitor of CRM1-mediated nuclear
export, the change in distribution of NP in the presence of
LMB strongly suggests that RNPs are exported from the nuclei
of virus-infected cells via a pathway involving CRM1. It has
been suggested that NS2 is involved in directing egress of the
RNPs from the nucleus (38), which could possibly occur
through interactions between CRM1 and NS2. Alternatively,
since much evidence also indicates the necessity of M1 for
RNP export, M1-CRM1 interactions could be involved. We
therefore examined the distribution of NS2 and M1 in influ-
enza virus-infected cells in the presence and absence of LMB.
In the absence of LMB, NS2 was distributed through both the
cytoplasm and nuclei of virus-infected cells but with generally
brighter fluorescence in the nuclei (Fig. 1e). In the presence of
LMB, this staining pattern was not significantly altered, with
the majority of cells still showing a mixture of nuclear and
cytoplasmic NS2 (Fig. 1f). In untreated cells, M1 was visible in
both the nuclei and cytoplasm of infected cells but at a higher
density in the nuclei (Fig. 1c). This pattern did not change in
the presence of LMB (Fig. 1d). These results were supported
by cell fractionation and Western blot analysis for M1 content,
which also showed no significant change in the partitioning of
M1 between the nuclear and cytoplasmic fractions of drug-
treated cells (data not shown). Thus, although RNP export was
inhibited when the CRM1 pathway was blocked, no effect on
the distribution of either NS2 or M1 was seen.
Next, we investigated whether the intranuclear distribution
of NP retained in the nucleus at late times postinfection by
LMB treatment was the same as that seen at early times before
the onset of RNP export. Virus-infected cells were harvested at
3.5 hpi in the presence and absence of LMB or at 9 hpi with
drug treatment and examined for NP distribution by indirect
immunofluorescence assay and confocal microscopy. In addi-
tion, to delineate the boundary of the nuclear envelope, cells
were double stained for Nup62, a structural component of the
NPC (6, 14). At 3.5 hpi in the absence of LMB, NP fluores-
cence was distributed throughout the nucleus in a stippled
pattern, entirely within the distinct from the peripheral ring of
Nup62 staining (Fig. 4a to c). This early pattern of intranuclear
NP staining was not altered in the presence of LMB (Fig. 4d to
f), indicating that inhibition of CRM1 function before the
onset of RNP export does not affect NP localization. However,
NP retained in the nucleus at 9 hpi by LMB treatment was not
distributed evenly throughout the nucleoplasm but, instead,
was largely confined to an area just inside the nuclear enve-
lope, producing a ring-like staining pattern (Fig. 4i). Thus,
inhibition of the CRM1-mediated export pathway not only
prevents nuclear export of NP but also results in specific relo-
calization of NP to a distinct area within the nucleus.
In the hypothesis invoking NS2 in RNP nuclear egress, com-
plexes of RNP in association with M1 and NS2 are the sub-
strate for nuclear export (38). Therefore, it was possible that
inhibition of RNP export by LMB would induce changes in the
intranuclear distribution of M1 and/or NS2 similar to those
seen with NP and that NP, M1, and NS2 would colocalize. To
test this hypothesis, we compared the intranuclear distribu-
tions of M1 and NS2 at 9 hpi in untreated and LMB-treated
cells and double stained the drug-treated cells for NP. In the
absence of LMB, M1 and NS2 were both distributed evenly
throughout the nucleus (Fig. 5a and e) in a pattern similar to
that of NP early in infection (Fig. 4c). However, the homoge-
neous distribution of M1 and NS2 throughout the nucleoplasm
was not altered by LMB addition (Fig. 5b and f) and only
limited colocalization of either polypeptide with the LMB-
induced annular NP staining pattern was seen (Fig. 5c, d, g,
and h). Thus, the intranuclear distribution of M1 and NS2 is
not altered by inhibition of the CRM1 export pathway and
both polypeptides localize largely independently of NP.
It was possible that the lack of an observable effect on NS2
localization after LMB treatment could be due to excess NS2
production beyond that required for export of RNPs via the
CRM1 pathway. To investigate this possibility, we examined
the effect of LMB on RNP export in cells infected with mN3,
a mutant avian influenza virus that is defective for segment 8
splicing and consequently expresses greatly reduced levels of
NS2 (44, 53). CEF cells were infected with either WT or mN3
influenza A/FPV/Rostock/34 virus, treated with LMB as before
at 34°C, harvested at 8 hpi, and examined for NP and NS2
localization. In addition, we also examined the effect of the
drug on protein synthesis by metabolic labeling of cells with
35S-methionine at 8 hpi, followed by SDS-PAGE and autora-
diography. In the absence of LMB, NP, M1/NS1, HA2, and
NS2 could readily be discerned in extracts from FPV-infected
cells (Fig. 3b, lane 2). In cells infected with mN3, the pattern of
protein synthesis appeared very similar except that significantly
reduced amounts of NS2 were observed (Fig. 3b, lane 4),
consistent with the known defect in splicing of segment 8 in this
virus (44). Comparison of proteins synthesized in the presence
of LMB revealed no significant differences for either virus,
FIG. 3. Effect of LMB on influenza virus polypeptide synthesis. (a)
BHK cells were infected with PR8 in the presence (lane 1) or absence
(lane 2) of 11 nM LMB (added at 1 hpi), harvested at 13 hpi, and
analyzed by SDS-PAGE and Western blotting using anti-PR8 serum.
Mock-infected cell lysate is shown in lane 3. The positions of uncleaved
HA, NP, and M1 are indicated by arrows. (b) CEF cells were infected
at 34°C with WT FPV or the ts mutant mN3 in the presence (1) or
absence (2) of LMB (added at 1 hpi) and then labeled with [35S]me-
thionine for 30 min before harvesting at 8 hpi. Lysates were analyzed
by SDS-PAGE and autoradiography. The positions of NP, HA2, M1/
NS1, and NS2 are indicated.
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except for a slight increase in the level of NS2 (Fig. 3b). Thus,
LMB does not inhibit synthesis of M1 or NS2 in CEF cells,
consistent with the lack of an observable effect on viral protein
synthesis in BHK cells (Fig. 1 and 3a). Next, we examined the
cellular distribution of NP and NS2 in cells infected with WT
and mN3 FPV by immunofluorescence assay. In the absence of
LMB, NP localized evenly throughout cells infected with WT
FPV (Fig. 6a). Thus, as expected, FPV NP is exported into the
cytoplasm at late times postinfection in CEF cells, although
unlike those of PR8-infected BHK cells, the nuclei do not
appear to empty. In the presence of LMB NP was restricted to
the nucleus, with only low levels seen in the cytoplasm (Fig.
6b), indicating that the nuclear export of RNPs had been
inhibited. These data indicate that inhibition of RNP nuclear
export in the presence of LMB is neither cell type nor virus
strain dependent. Cells infected with mN3 in the absence of
LMB showed the same distribution of NP throughout the cells
as those infected with WT virus (Fig. 6c). In the presence of
LMB, NP was retained in the nucleus (Fig. 6d), indicating that
reduced levels of NS2 had no effect on either the normal
export of RNPs or their nuclear retention when CRM1-medi-
ated export was blocked. Consistent with the decreased NS2
synthesis observed by metabolic labeling (Fig. 3b), the level of
NS2 fluorescence was lower than that seen with WT FPV (Fig.
6e to h), although still significantly above background levels
(Fig. 6i and j). However, the distribution of NS2 in untreated
CEF cells infected with either FPV or mN3 was essentially the
same for the two viruses in that the protein was distributed
throughout the cell and it was not possible to distinguish the
nuclei (Fig. 6e and g). In cells treated with LMB, no obvious
difference was seen in the distribution of NS2 compared with
untreated cells infected with either virus, suggesting that the
inhibition of CRM1-mediated nuclear export had no effect on
NS2 localization. In addition, while both WT FPV and mN3
NPs displayed the characteristic peripheral nucleoplasmic
staining pattern at late times after LMB treatment, the in-
tranuclear distribution of their NS2 polypeptides remained
unchanged (data not shown). Thus, even in the presence of
minimal amounts of NS2, LMB has no obvious effects on the
intracellular distribution of this protein.
Effect of LMB on export of transiently expressed virus pro-
teins. LMB inhibited the nuclear export of NP in virus-infected
FIG. 4. Effect of LMB on the intranuclear distribution of NP. BHK cells were infected with PR8 in the absence or presence of 11 nM LMB
(added at 1 hpi) and harvested at the indicated times postinfection. Cells were stained for NP (green) and Nup62 (red), and single optical planes
of focus were examined by confocal microscopy. The green channels in panels h and i were captured at lower sensitivity to keep the maximum
fluorescence intensity within the linear range of the detector.
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cells but had no apparent effect on M1 or NS2 distribution.
Since current models for RNP export suggest roles for NS2
and/or M1, it was somewhat surprising that LMB had no effect
on either protein. To examine this further, the effect of LMB
on the localization of individual virus proteins was tested. BHK
cells were infected with a recombinant vaccinia virus express-
ing T7 RNA polymerase and then transfected with plasmids
expressing NP, M1, or NS2 under the control of a T7 pro-
moter. We have previously shown that the distribution of NP
alters according to the level of expression: cells transfected
with a low plasmid dose (0.03 mg of DNA/2 3 104 cells)
generally show a nuclear staining pattern of NP, but with
increasing plasmid doses, the polypeptide tends to accumulate
in the cytoplasm (9, 33). We therefore transfected cells with
each plasmid at a range of doses, in the case of NP to ensure
that cytoplasmic accumulation occurred to some degree, and
for M1 and NS2 to test whether a change in the distribution of
the protein occurred with various expression levels. In some
cases, cell cultures were treated with LMB 3 h after transfec-
tion, following which all of the cells were harvested at 5 h
posttransfection, the subcellular localization of the influenza
virus polypeptides was examined by immunofluorescence as-
say, and cells were scored N, N/C, or C. The results are ex-
pressed graphically as a percentage of the total cells counted,
and examples of each staining pattern (obtained in the absence
of LMB) for the three polypeptides are shown to the left of the
corresponding graphs (Fig. 7). Cells transfected with 0.1 mg of
pKT5 displayed the expected NP localization pattern, with the
largest proportion (approximately 50%) of the cells containing
NP in both the nucleus and cytoplasm, but with substantial
populations (about 25% each) showing either predominantly
nuclear or cytoplasmic staining (Fig. 7a). At higher plasmid
doses, the pattern of NP distribution became more more cy-
toplasmic, with greater than 60% of the cells scored C and only
around 10% scored N (Fig. 7a). This is consistent with our
previous observations (9, 33). However, irrespective of the
plasmid quantity used, the addition of LMB altered the distri-
bution pattern of NP, decreasing the proportion of cells show-
ing cytoplasmic accumulation and increasing the number with
predominantly nuclear protein (Fig. 7a). This effect was most
pronounced at a dose of 0.3 mg of pKT5, where the proportion
of transfected cells with nuclear NP increased from around
10% in the absence of drug to nearly 50% in its presence.
Concomitantly, the number of cells with a cytoplasmic staining
pattern decreased from over 70 to 15%. When similar exper-
iments were carried out using a plasmid encoding M1, in the
absence of LMB, the majority of the M1-expressing cells
(around 70%) showed an even distribution of the polypeptide
between the nucleus and the cytoplasm, with only a low per-
centage of cells showing predominantly nuclear fluorescence
(Fig. 7b). In contrast to the behavior of NP, the pattern of M1
localization did not alter significantly with the plasmid dose,
even when higher or lower ranges were tried (data not shown).
Also in contrast to the behavior of NP, the distribution of M1
did not change significantly in the presence of LMB (Fig. 7b).
Cells transfected with NS2 showed a staining pattern similar to
that of those expressing M1, with the majority scored N/C,
although a slightly higher percentage showed predominantly
nuclear protein (Fig. 7c). Similarly, no change in localization
pattern was seen with plasmid dose alteration (even when
larger amounts of DNA were transfected; data not shown) and
no increase in nuclear accumulation was observed in cells ex-
pressing NS2 in the presence of LMB (Fig. 7c). We therefore
found no evidence that either M1 or NS2 interacts with the
CRM1 pathway in the absence of other influenza virus com-
ponents. In contrast, inhibition of the CRM1-mediated nuclear
export pathway results in nuclear retention of NP, indicating
FIG. 5. Effect of LMB on the intranuclear distribution of M1 and NS2. BHK cells were infected with PR8 in the absence (2) or presence (1)
of 11 nM LMB and harvested at 9 hpi. Cells were stained for either M1 (green) or NS2 (red) and costained for NP. Single optical planes of focus
captured by confocal microscopy are shown. Panels b, c, and d and f, g, and h, respectively, are of the same cells.
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that NP interacts with this pathway in the absence of other
influenza virus proteins.
To further investigate the role of CRM1-mediated export
pathway plays in determining intracellular localization of in-
fluenza virus polypeptides, we tested the effect of overexpres-
sion of CRM1 on the localization of NP, M1, and NS2. Plas-
mids encoding influenza virus polypeptides were individually
cotransfected with 0.2 mg of a construct expressing CRM1 (2)
or with pCDNA-3 containing no insert, and the localization of
the influenza virus polypeptides was analyzed by indirect im-
munofluorescence assay as before. In the absence of exoge-
nous CRM1, the percentage of NP-expressing cells showing
predominantly cytoplasmic fluorescence increased from 3% at
the lowest dose of pKT5 to 15% at the highest (Table 1). When
CRM1 was coexpressed with NP, the distribution of NP be-
came more cytoplasmic at each dose of pKT5. This effect was
most pronounced at the lowest plasmid dose (0.03 mg) (where
NP was predominantly nuclear in the absence of exogenous
CRM1), as overexpression of exogenous CRM1 increased the
percentage of transfected cells with cytoplasmic NP from 3 to
38% (Table 1). In six independent experiments involving a
total of 17 paired samples, cotransfection of CRM1 resulted in
a significant increase in cytoplasmic NP in every case at all of
the pKT5 doses tested (x2 statistic, P , 0.001 on 15 occasions
and P , 0.01 twice). Under transfection conditions which re-
sulted in substantial numbers of cells with cytoplasmic NP in
the absence of CRM1, cotransfection of CRM1 resulted in a
twofold increase in nuclear exclusion (2.3 6 0.3 [n 5 5]). In
low-dose pKT5 transfections where the majority of NP-ex-
pressing cells showed nuclear staining in the absence of CRM1,
the average fold increase in cytoplasmic staining after cotrans-
fection was 23.8 6 8.5 (n 5 4) (data not shown). Furthermore,
addition of LMB to cells expressing CRM1 and NP prevented
the increase in cytoplasmic accumulation of NP at higher doses
of pKT5, retaining NP in the nucleus at levels similar to those
of cells expressing NP alone without drug (Table 1). At the
lowest dose of pKT5, which showed the most dramatic CRM1-
dependent increase in NP export, addition of LMB partially
reversed the effect, reducing the proportion of cells with pre-
dominantly cytoplasmic NP by approximately twofold (Table
1). In contrast, overexpression of CRM1 had little effect on the
distribution of M1, causing no more than a 1.5-fold increase in
the proportion of cells with cytoplasmic fluorescence (Table 1).
In three independent experiments, the greatest increase in
cytoplasmic M1 seen was 1.8-fold (average, 1.2 6 0.4 [n 5 9])
and overall there was no statistically significant change in the
intracellular distribution of the polypeptide (data not shown).
LMB treatment of cells cotransfected with M1 and CRM1 also
had no major effect on M1 localization (Table 1). When similar
CRM1 cotransfection experiments were carried out with NS2,
no significant increase in the proportion of cells with predom-
inantly cytoplasmic NS2 was seen (data not shown). However,
coexpression of CRM1 consistently caused a slight reduction in
the number of transfected cells with predominantly nuclear
NS2, which was not reversible by the addition of LMB (Table
1). In three replicate experiments, the maximum decrease in
the proportion of cells with predominantly nuclear NS2 was
1.6-fold (average, 1.4 6 0.2 [n 5 6]) and the effect was not
consistently statistically significant (Table 1 and data not
shown). Thus, when expressed in the absence of other influ-
enza virus polypeptides, NP is strongly biased toward cytoplas-
mic accumulation by the overexpression of CRM1. However,
the distribution of M1 is unaffected and that of NS2 is only
weakly affected, if at all.
The increased cytoplasmic accumulation of NP after CRM1
overexpression further supports the hypothesis that NP inter-
acts with the CRM1 nuclear export pathway in the absence of
other influenza virus proteins. However, as CRM1 is also in-
volved in the export of cellular RNAs (8, 15, 45, 47), it was
possible that in the absence of influenza virus RNA, NP was
binding nonspecifically to cellular RNA complexes destined for
export, rather than interacting directly with CRM1. To inves-
tigate this possibility, we tested the effect of overexpression of
FIG. 6. Effect of LMB treatment on the intracellular localization of
NP and NS2 in FPV-infected cells. CEF cells were infected (or mock
infected) with either WT or mN3 FPV at 34°C, incubated from 1 hpi
in the absence or presence of 11 nM LMB, and harvested at 8 hpi.
Cells were stained for NP (a to d) or NS2 (e to j) and examined by
confocal microscopy. Images were generated using an extended-focus
algorithm.
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CRM1 on the cellular distribution of an NP mutant that is
defective for RNA binding activity (13). NP R267-A was ex-
pressed at a range of plasmid doses, as before, and the effects
of overexpression of CRM1 in the presence and absence of
LMB were examined. In the absence of exogenous CRM1, the
mutant NP localized essentially the same way as WT protein
(Table 1). However, the mutant polypeptide showed a striking
difference in localization when expressed in the presence of
exogenous CRM1, with up to 90% of transfected cells showing
cytoplasmic NP. The increased cytoplasmic accumulation of
R267-A was partially reversible by LMB treatment (Table 1).
Similar results were obtained with a second mutant NP, S314-
N, which has a ts lesion that renders the protein unable to bind
RNA at 37°C (data not shown; reference 33). These results
FIG. 7. Effect of LMB on the distribution of NP, NS2, and M1 in transfected cells. BHK cells were infected with vTF7 at an MOI of 10 PFU/cell
and then transfected 2 h later with the indicated amounts of plasmid DNA encoding NP, NS2, or M1. At 3 h posttransfection, cells were overlaid
with fresh medium containing either 11 nM LMB or no drug and harvested 2 h later. Cells were analyzed by immunofluorescence assay using
antibodies for NP, M1, or NS2 and scored as follows for the localization pattern of the influenza virus protein: N, predominantly nuclear; N/C
distributed throughout the cell; C, predominantly cytoplasmic. Examples of the staining patterns are shown on the right. The number of cells
showing each distribution pattern was expressed as a percentage of the total cell count. The average and range of two independent experiments
are shown.
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indicate that the CRM1-dependent export of NP operates in
the absence of an NP-RNA interaction and is therefore un-
likely to be due to fortuitous association with host cell RNAs.
In vitro analysis of interactions among NP, NS2, and com-
ponents of the cellular nuclear trafficking machinery. The
observation that the intracellular localization of NP is sensitive
to modulation of the CRM1 export pathway raises the possi-
bility that NP contains an NES and interacts directly with
CRM1. To test this hypothesis, we examined the ability of NP
fusion proteins to bind CRM1 in vitro. For comparison, we
also examined the ability of NP to bind to hSRP-1, a previously
characterized cellular NP binding protein from the importin a
family (37, 49), to itself, since the polypeptide is known to
self-associate (12, 40, 43), and to NS2, as NP is generally held
not to interact directly with NS2 (10, 54). Radiolabeled CRM1,
hSRP-1, NP, and NS2 were expressed by coupled transcription
and translation of the appropriate plasmid templates in rabbit
reticulocyte lysate (7), and aliquots of the in vitro-translated
material were incubated with either GST, MBP, or NP fused to
GST or MBP (GST-NP or MBP-NP, respectively). After sub-
sequent incubation with glutathione-Sepharose or amylose
resin, as appropriate, bound material was collected and washed
by centrifugation and analyzed by SDS-PAGE and autoradiog-
raphy. As we have shown previously (12), NP self-associates
specifically and efficiently in this assay system, as substantial
quantities of the in vitro-translated NP bound to GST-NP but
not to GST alone (Fig. 8, lanes 4 to 6). In contrast, no detect-
able NS2 bound to either GST or GST-NP, (Fig. 8, lanes 10 to
12), consistent with earlier studies that failed to find evidence
for a direct interaction between NS2 and NP (10, 54). How-
ever, hSRP-1 did bind specifically to GST-NP (Fig. 8, lanes 7 to
9), consistent with the interaction between the polypeptides
previously identified by yeast two-hybrid and coimmunopre-
cipitation analyses (37, 49). Moreover, in vitro-translated
CRM1 bound to GST-NP and MBP-NP but not GST or MBP
alone (Fig. 8, lanes 1 to 3, 14, and 16), and comparison of the
ratios of bound to input polypeptides suggested that the ap-
parent affinity of the interaction between CRM1 and NP was
similar to that of the NP-NP or NP–hSRP-1 interaction. How-
ever, addition of LMB to the reaction mixtures did not affect
the interaction between MBP-NP and CRM1 (lane 15) or that
between GST-NP and CRM1 (data not shown). Thus, NP
binds CRM1 in vitro, consistent with the effect of up- or down-
regulation of the CRM1 nuclear export pathway on the intra-
cellular localization of NP.
DISCUSSION
Influenza virus RNPs display a biphasic pattern of intracel-
lular localization during infection. At early times, they reside in
the nucleus, where virus transcription takes place, but at later
times in infection, they are exported to the cytoplasm to allow
their packaging into progeny virions. The current hypothesis to
explain this phenomenon holds that the late viral polypeptides
M1 and NS2 enter the nucleus and bind sequentially to the
RNPs and that the ability of NS2 to interact with components
of the NPC directs export of the complex (38). In light of this
model, it has been suggested that NS2 be renamed NEP (nu-
clear export protein) (38). Here, we show that treatment of
cells with the drug LMB blocks nuclear export of RNPs,
strongly suggesting that this process requires the cellular ex-
port receptor CRM1, rather than a direct interaction of RNPs
or RNP complexes with the NPC. Although LMB is generally
held to be a specific inhibitor of the CRM1 pathway (8, 18, 24,
25, 36), we cannot formally exclude the possibility that the drug
also affects an as yet uncharacterized export function, either
directly or indirectly. However, no effect of LMB treatment on
the distribution of Ran or Rch-1, a member of the importin a
family, was observed (data not shown), suggesting that the
importin a- and NTF2-mediated nuclear import pathways and
the CAS-mediated export pathway were still functional (27,
42). Similarly, the failure of LMB treatment to inhibit viral
protein synthesis argues that the export pathway(s) responsible
for viral mRNA egress remains functional (and that this path-
TABLE 1. Effect of CRM1 overexpression on NP, M1, and
NS2 localization
Polypeptide
and plasmid
dose (mg)
Without
CRM1a
With
CRM1b
With CRM1 1
LMBb
NP
0.3 15 28 (1.9) 14 (0.9)
0.1 11 24 (2.2) 8 (0.7)
0.03 3 38 (13) 17 (5.7)
NP R267-A
0.3 10 51 (5.1) 47 (4.7)
0.1 5 81 (16.2) 64 (12.8)
0.03 0 88 (.88) 89 (.89)
M1
0.3 5 5 (1.0) 7 (1.4)
0.1 4 6 (1.5) 5 (1.3)
0.03 1 1 (1.0) 2 (2.0)
NS2
0.3 63c 43 (1.5) 47 (1.3)
0.1 65 54 (1.2) 51 (1.3)
0.03 76 47 (1.6) 57 (1.3)
a Percentage of cells scored C.
b The fold change in the percentage of cells is in parentheses.
c Percentage of cells scored N.
FIG. 8. In vitro interaction between NP and CRM1. Radiolabeled
in vitro-translated CRM1, NP, hSRP-1, and NS2 were analyzed by
SDS-PAGE and autoradiography before (T) or after binding to GST
(G), MBP (M), or GST-NP (N in lanes 3, 6, 9, and 12) or MBP-NP (N
in lanes 15 and 16) immobilized on agarose beads. LMB (11 nM) was
included in the reaction mixture run in lane 15 (N1). The values on
the left are molecular mass markers (kilodaltons).
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ways does not involve CRM1). Therefore, LMB treatment
does not result in a general inhibition of nucleocytoplasmic
transport in the systems examined here. Furthermore, the ob-
servation that overexpression of CRM1 biased NP toward cy-
toplasmic accumulation in an LMB-sensitive manner (Table 1)
strongly suggests that the inhibitory target of LMB in this
system is CRM1. We therefore conclude that the effects of the
drug on influenza virus polypeptide localization are specific.
The inhibitory effect of LMB on RNP export was not confined
to a particular strain of virus or cell but was observed with the
PR8, FPV, and A/Udorn/72 strains in primary CEFs, immor-
talized fibroblasts such as BHK, CV1, and Cos cells, and po-
larized epithelial MDCK cells (Fig. 1, 2, 4, and 6 and data not
shown). This suggests that use of the CRM1 pathway is a
general feature of influenza A viruses.
Part of the experimental support of the NEP hypothesis
comes from the identification of a sequence within NS2 that
acts as an NES when transplanted onto another polypeptide
(38), raising the possibility that it is NS2 that interacts with
CRM1. However, the LMB-induced block in RNP export was
not accompanied by a major change in the nucleocytoplasmic
distribution of NS2 or M1 (Fig. 1) and such a redistribution
might be expected if export occurs via an RNP-M1-NS2 com-
plex. Unlike NP in PR8-infected BHK cells, the M1 and NS2
polypeptides are ordinarily resident in substantial quantities
within the nucleus late in infection (Fig. 1) and are therefore
perhaps less likely to show decreased cytoplasmic and in-
creased nuclear accumulation after LMB treatment. However,
a larger proportion of NS2 in FPV-infected CEF cells is cyto-
plasmic, and although this provides a more sensitive back-
ground against which to observe increased nuclear accumula-
tion of the polypeptide after CRM1 inhibition, no change in its
distribution was observed (Fig. 6). Moreover, neither NS2 nor
M1 showed any apparent intranuclear redistribution after
LMB treatment (Fig. 5). This is in contrast to the striking
change observed with NP, where at early times postinfection
(when the polypeptide is ordinarily resident within the nucle-
us), the polypeptide displayed diffuse intranuclear staining, but
when retained artificially at late times by LMB treatment, it
localized to a distinctive peripheral ring within the nucleo-
plasm (Fig. 4). In the case of M1, our observations are com-
patible with the observation that although M1 is required for
RNP export, it does not necessarily accompany the exported
RNPs in detectable amounts (41, 51, 52). However, RNPs have
been shown to be tightly associated with the nuclear matrix (4,
22) and it has been suggested that M1 is required for their
release (4, 56). As Bui and colleagues pointed out (4), this
would effectively make RNP export a two-stage process, which
is consistent with the change in intranuclear distribution of NP
we observed between early and late times postinfection in the
absence of nuclear export (Fig. 4). Experiments to test this
hypothesis are currently in progress.
The failure to observe any redistribution of NS2 after LMB
treatment is perhaps more surprising, as its putative role as the
actual transport factor would predict at least one round of
shuttling per molecule of NS2. One could perhaps argue that
the unchanged cellular localization of NS2 following LMB
treatment arises from an excess of the polypeptide and its
nonstoichiometric requirement for RNP export. However, the
behavior of the FPV mutant mN3 argues against this hypoth-
esis. This virus is able to replicate to reasonably high titers in
tissue culture despite a segment 8 splicing defect which results
in the synthesis of 5% or less of the normal amount of NS2 (44,
53). Consistent with the production of a normal infectious titer,
the mN3 virus showed no obvious defect in the transport of
RNPs from the nucleus to the cytoplasm (Fig. 6). Moreover, in
cells infected with mN3 under conditions where the CRM1
pathway was blocked, there was no obvious alteration in the
distribution of NS2, either at the level of nucleocytoplasmic
distribution (Fig. 6) or at the intranuclear level (data not
shown). Thus, if NS2-RNP complexes are the substrate for
nuclear export, then only a minor fraction of the total NS2
content is required or the interaction is too transitory to be
observed by the techniques used here.
In recent years, much evidence has accumulated to suggest
that NP possesses the intrinsic ability to interact with a nuclear
export pathway. Despite containing multiple nuclear localiza-
tion signals (49, 50), exogenously expressed NP is not neces-
sarily resident in the nucleus but can accumulate in the cyto-
plasm, depending upon the phosphorylation status of the cell,
the time and level of NP expression, and its ability to bind
F-actin (5, 9, 35). Furthermore, non-RNP-associated NP has
been shown to shuttle between the nucleus and the cytoplasm
(51). We show here that in the absence of other influenza virus
polypeptides, cytoplasmic accumulation of NP was greatly re-
duced by LMB treatment (Fig. 7), mimicking the effect seen on
RNPs in virus-infected cells (Fig. 1, 2, and 6). In contrast,
overexpression of CRM1 strongly biased exogenous NP toward
a cytoplasmic location (in a manner that was not dependent
upon the ability of the polypeptide to bind RNA), but this was
reversible by simultaneous LMB treatment (Table 1). Overall,
this provides strong evidence that NP interacts with the CRM1
pathway in the absence of other influenza virus polypeptides.
In contrast, the distribution of exogenously expressed NS2 and
M1 showed very little alteration after up- or down-regulation
of CRM1 activity (Fig. 7; Table 1), similar to the lack of effect
of LMB on the distribution of each of these proteins in the
context of virus infection (Fig. 1, 5, and 6). Consistent with data
obtained from infected or transfected cells, we also found
evidence for an NP-CRM1 interaction in vitro (Fig. 8). How-
ever, the in vitro interaction between NP and CRM1 was not
sensitive to LMB (Fig. 8) but it is not clear whether LMB
modification of CRM1 prevents its binding to NES sequences.
Although the studies of Fornerod et al. (15) and Kudo et al.
(24) demonstrated LMB inhibition of the formation of a
CRM1-RanGTP-NES peptide complex and a CRM1-NES
peptide complex, respectively, the concentrations of both the
NES-containing substrate and LMB used were much (;1,000-
fold) higher than those used in this study. We also note that the
Rev polypeptide of human immunodeficiency virus interacts
with CRM1 in vitro in both LMB-sensitive and LMB-insensi-
tive manners, with LMB only inhibiting binding when in the
presence of RanGTP (1). Unfortunately, we have not yet been
able to obtain an anti-CRM1 serum that is functional in im-
munofluorescence to perform NP-CRM1 colocalization stud-
ies. However, the peripheral nuclear distribution of NP ob-
tained after LMB treatment (Fig. 4) is similar to the nuclear
staining pattern shown for CRM1 in non-drug-treated cells
(16).
The finding that NP interacts with the CRM1 export path-
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way in the absence of other influenza virus components raises
the possibility of NS2-independent RNP export. Such a hy-
pothesis is consistent with the lack of NS2 redistribution after
CRM1 inhibition (Fig. 1, 5, and 6). We also note the recent
experiments of Bui et al. (4) in which RNP export was blocked
by treatment with the protein kinase inhibitor H7 but restored
by the addition of exogenous M1 in the absence of detectable
NS2. In addition, work analyzing the requirements for the
formation of influenza virus-like particles has demonstrated
that NS2 is dispensable for packaging of a synthetic genome
segment (A. Portela, personal communication). However, strong
evidence suggesting the requirement of NS2 for RNP export
during virus infection has come from recent work showing that
NP is retained in the nuclei of cells infected with an NS2
knockout virus generated by reverse genetics (Y. Kawaoka,
personal communication). Therefore, it is possible that the di-
rect interaction of RNPs with the CRM1 export pathway rep-
resents a redundant alternative to an NS2-mediated pathway,
and/or that virus strain and cell type variations are important.
In support of a hypothesis of multiple RNP export mecha-
nisms, inhibition of the CRM1 pathway failed to completely
block the movement of NP to the cytoplasm, as assessed by cell
fractionation studies (Fig. 2). In addition, when the effect of
the drug on virus yield was titrated, the maximal decrease in
virus titer reached was 90 to 95% (data not shown). While this
is a magnitude decrease similar to that caused by H7, another
inhibitor of RNP export (26), it implies that sufficient RNPs
are still reaching the plasma membrane to form some progeny
virus. However, considering the dramatic change in NP local-
ization shown by immunofluorescence assay and cell fraction-
ation and the fact that .90% of the virus titer was lost after
LMB treatment, we would argue that, overall, the CRM1 path-
way plays a predominant role in influenza virus RNP export.
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